SpringWorks is hiring a payer and access marketer to run "non-personal promotion" for "payers, population-based decision-makers, pharmacists, GPOs". Yet ogsiveo.com/hcp is built only for prescribers: there is no managed-care or pharmacy page, and the Connect With Us form offers only Oncology, Surgery, NP/RN/PA or Other, so a P&T pharmacist or payer has no named way in.
First action
List the approved payer materials that exist today and the gaps.
How to measure it
Payer and pharmacist contacts from the site
- Now
- –
- Target
- 50 a quarter
- By
- 2 quarters
Steps
Inventory materials
Approved payer, coding and ordering resources.
Associate Director, Payer & Access Marketing 1 week
Design the section
Dossier request, resources, contact route.
Omnichannel Marketing Lead 1 week
Update the form
Add payer, pharmacist and GPO roles with routing.
Omnichannel Marketing Lead 3 days
MLR review
Every page and form label.
Medical, Legal and Regulatory review 3 weeks
Launch
Link from the HCP navigation and access page.
Omnichannel Marketing Lead 1 day
Brief the field
Account directors and Field Access Managers share the link.
Associate Director, Payer & Access Marketing 1 week
Measure
Requests and contacts by audience type.
Commercial Operations monthly
Why it works
Add a "Managed care and pharmacy" section to the HCP site: an AMCP-format dossier request, the approved value and coding resources already used by the field (such as the ICD-10 flashcard and ordering guide), specialty pharmacy and distribution details, and a contact route to the account team. Add "Payer / PBM", "Health-system or specialty pharmacist" and "GPO / IDN" to the Connect form so those contacts reach the right team. Take every page through MLR before launch.
Access decision-makers look for a dossier and a contact before they meet anyone. A clear route lets the new non-personal programme start from owned channels and gives the account directors a link to send.
Ready to use
ChecklistManaged care section launch list
[ ] AMCP-format dossier request form [ ] Approved coding and ordering resources [ ] Specialty pharmacy and distribution details [ ] Contact route to account directors [ ] Payer / PBM, pharmacist, GPO / IDN options on Connect With Us [ ] US-audience gate [ ] MLR approval recorded [ ] Request tracking by audience
Risks and how to handle them
Promotional rules for payer communications
Keep content to approved, on-label materials reviewed by MLR.
Requests from outside the US
Gate with a US-audience confirmation as on the rest of the site.
Evidence
- HiringAssociate Director, Payer & Access Marketing - US Rare Tumors (OGSIVEO) (Boston hybrid, posted September 14, 2026): will "shape and execute the OGSIVEO value proposition across US market access channels" for "payers, population-based decision-makers, pharmacists, GPOs, and external thought leaders"; will "Head the strategy and execution of non-personal promotion initiatives for market access audiences", drive "pull-through of GPO strategy", build "measurement frameworks", move work through MLR review, and "equip field teams with coordinated value messaging in a more competitive market"; external groups named include "PBMs", "COA, NCODA, ASCO, NCCN".Source
- Your websiteogsiveo.com HCP site (sitemap checked October 23, 2026): sections for desmoid treatment, overview and data, dosing and management, patient support and access, practice resources, patient profiles, videos and Connect With Us; no page for payers, formulary decision-makers, pharmacists or GPOs. The Connect With Us form lists specialties "Oncology", "Surgery", "NP/RN/PA" and "Other". The access page describes SpringWorks CareConnections, Quick Start and Bridge programs, a commercial copay program, Field Access Managers and specialty pharmacy ordering.Source
- HiringMedical Science Liaison / Senior MSL - West Region (WA, OR, CA, NV, AZ, HI, AK; board updated October 15, 2026): builds scientific relationships with KOLs "in academic centers and community practices", staffs "disease state booths" at congresses, and serves "as a Medical Affairs lead for disease state and outcomes-based product presentations to managed-care customers".Source
- News coverageThe FDA accepted Immunome's New Drug Application for varegacestat, an investigational gamma secretase inhibitor for adults with desmoid tumors, with an action date of April 28, 2027. SpringWorks' NF1 page notes that the FDA "approved another drug from the MEK inhibitor class for the treatment of children with NF1-PN".Source